Biologic and targeted synthetic therapies in juvenile idiopathic arthritis: a review of current and emerging therapeutic agents

Despite substantial therapeutic progress, achieving sustained, drug-free remission remains a challenge for many JIA patients. Precision medicine - guided by predictive biomarkers, pharmacovigilance data, and real-world evidence - is essential for optimizing individualized care. Future efforts should prioritize the development of safer, more tolerable, and accessible therapies tailored to the unique needs of pediatric populations.